Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) will likely be posting its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Seres Therapeutics to post earnings of ($0.17) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Seres Therapeutics Stock Performance

NASDAQ:MCRB opened at $0.72 on Wednesday. The firm has a market cap of $125.08 million, a price-to-earnings ratio of -3.12 and a beta of 2.19. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $1.53. The firm has a 50-day moving average price of $0.81 and a two-hundred day moving average price of $0.84.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. StockNews.com upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 6th. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a research note on Thursday, November 14th. Finally, Chardan Capital restated a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Seres Therapeutics has an average rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.